Philadelphia, August 12, 2025 — BiotechReporter.news — Passage Bio, Inc. (Nasdaq: PASG) reported its second-quarter financial results, highlighting the completion of dosing for Cohort 2 in its upliFT-D study and the submission of an amended study protocol to global trial sites and health authorities.
Updated interim data indicated that PBFT02 continues to show robust and durable elevation in cerebrospinal fluid progranulin (PGRN) levels and improvement in plasma neurofilament light chain (NfL), a disease progression biomarker, compared to natural history. The company’s cash runway extends into the first quarter of 2027.
Will Chou, M.D., president and chief executive officer of Passage Bio, expressed encouragement about the emerging data from the upliFT-D clinical trial, emphasizing PBFT02’s potential as a differentiated therapy for the FTD-GRN patient community. The company is focused on initiating enrollment for its third FTD-GRN and first FTD-C9orf72 patient cohorts following protocol amendment approval at trial sites, and plans to engage with health authorities in the first half of 2026 for guidance on the registrational pathway for the program in FTD-GRN.
Contact:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com
Source: Passage Bio
